Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)
NCT ID: NCT00336219
Last Updated: 2012-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
628 participants
INTERVENTIONAL
2006-08-31
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
NCT00163306
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)
NCT00326027
Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)
NCT00246909
Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)
NCT00561730
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
NCT00703534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Pantoprazole 40 mg
Pantoprazole
Symptom Assessment after treatment with Pantoprozole 40 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pantoprazole
Symptom Assessment after treatment with Pantoprozole 40 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Outpatients
* History of GERD-related symptoms for at least 6 months prior to study inclusion
* Endoscopically confirmed erosive GERD or non-erosive GERD
Exclusion Criteria
* PPIs during last 7 days prior to study start
* Systemic glucocorticoids or non-steroidal anti-inflammatory drugs including COX-2 inhibitors during the last 28 days prior to study start; except regular intake of acetylsalicylic acid up to a daily dose of 163 mg/day
* Intake of PPIs in combination with antibiotics for eradication of H. pylori
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nycomed
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerald Holtmann, Prof.
Role: PRINCIPAL_INVESTIGATOR
Department of Gastroenterology, Hepatology and General Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, Australia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altana Pharma/Nycomed
Bondi Junction, , Australia
Altana Pharma/Nycomed
Box Hill, Victoria, , Australia
Altana Pharma/Nycomed
New South Wales, , Australia
Altana Pharma/Nycomed
South Australia, , Australia
Altana Pharma/Nycomed
Feldbach, , Austria
Altana Pharma/Nycomed
Graz, , Austria
Altana Pharma/Nycomed
Stockerau, , Austria
Altana Pharma/Nycomed
Vienna, , Austria
Altana Pharma/Nycomed
Wiener Neustadt, , Austria
Altana Pharma/Nycomed
Amberg, , Germany
Altana Pharma/Nycomed
Aschersleben, , Germany
Altana Pharma/Nycomed
Berlin, , Germany
Altana Pharma/Nycomed
Berlin, , Germany
Altana Pharma/Nycomed
Berlin, , Germany
Altana Pharma/Nycomed
Cologne, , Germany
Altana Pharma/Nycomed
Cologne, , Germany
Altana Pharma/Nycomed
Freising, , Germany
Altana Pharma/Nycomed
Germersheim, , Germany
Altana Pharma/Nycomed
Grünstadt, , Germany
Altana Pharma/Nycomed
Jülich, , Germany
Altana Pharma/Nycomed
Köthen, , Germany
Altana Pharma/Nycomed
Künzing, , Germany
Altana Pharma/Nycomed
Landsberg, , Germany
Altana Pharma/Nycomed
Langen, , Germany
Altana Pharma/Nycomed
Leipzig, , Germany
Altana Pharma/Nycomed
Ludwigshafen, , Germany
Altana Pharma/Nycomed
Lüneburg, , Germany
Altana Pharma/Nycomed
Mönchengladbach, , Germany
Altana Pharma/Nycomed
München, , Germany
Altana Pharma/Nycomed
Potsdam-Babelsberg, , Germany
Altana Pharma/Nycomed
Reinfeld, , Germany
Altana Pharma/Nycomed
Saarbrücken, , Germany
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Győr, , Hungary
Altana Pharma/Nycomed
Hatvan, , Hungary
Altana Pharma/Nycomed
Kaposvár, , Hungary
Altana Pharma/Nycomed
Kistarcsa, , Hungary
Altana Pharma/Nycomed
Miskolc, , Hungary
Altana Pharma/Nycomed
Szentes, , Hungary
Altana Pharma/Nycomed
Vác, , Hungary
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BY1023/M3-343
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.